European Academy of Allergy and Clinical Immunology Congress (EAACI 2017)
Helsinki Exhibition and Convention CentreHelsinki, FINLAND Visit the Venue to read more
We very much look forward to hosting the EAACI Congress 2017, from 17 – 21 June, and to wishing you a warm welcome to Finland and the beautiful city of Helsinki.
The theme for the Helsinki Congress is “On the road to prevention and healthy living”. A unifying theme for EAACI, this represents the next step in making our patients’ lives healthy, despite their allergies. With more than half of all Europeans soon expected to suffer from allergy, ensuring our patients have a better quality of life, despite the allergy epidemic, is an obvious goal for EAACI. It is also a theme in the true Finnish Allergy Programme spirit: wishing good life for all people.
The EAACI Congress 2017 is to be held in the Messukeskus Congress Center, which is easily reached from the city centre in just 5 minutes by train. This recently renovated venue offers the highest standards in conference facilities, with well-equipped and easy-to-find session rooms and a full digital environment.
Helsinki itself is a modern city with all its attractions and services within walking distance. It has excellent hotels and restaurants for all budgets, monuments, parks, shopping, market squares and other places to visit, as well as the sea with picturesque boat rides in the Helsinki archipelago, a lively nightlife and even free bicycles provided by the city. Helsinki manages to combine big city life with the green and beautiful countryside in which it resides. With something for all tastes, Helsinki is a unique Nordic experience.
Welcome to Helsinki!
EAACI Congress 2017 Chair
Group registrations not allowed
Accompanying persons not allowed
We don’t accept Online Abstracts
Helsinki Exhibition and Convention Centre (Helsingin Messukeskus)
The EAACI Scientific Programme Committee and the Local Organising Committee welcome the submission of original contributions for oral and poster presentation at the Congress.
DEADLINE: 15 JANUARY 2017 at 24:00 CET
Abstracts received after this date will not be considered.
Instructions to authors
Carefully read the guidelines below before submitting your abstract. Acknowledgement of the receipt of your submission will be sent to the corresponding author’s e-mail address immediately upon submission. If you do not receive the confirmation e-mail, please do not submit the abstract again, instead please contact the Abstract team at firstname.lastname@example.org for advice.
Invited speakers are not required to submit abstracts to the lectures they are invited for.
• Abstracts can only be submitted electronically through the Congress website.
• You are allowed to be the presenting author of more than one abstract.
• You are allowed to be a co-author of more than one abstract.
• Submission of similar abstracts from the same group is discouraged.
• Abstracts will only be considered for presentation if they are not published or submitted for presentation elsewhere.
When entering the abstract submission system for the first time, you will be asked to create a profile. Through your account you will be able to access your personal page to submit one or several abstracts. You can edit your abstracts until the submission deadline, 15 January 2017.
Abstract language and length
Abstracts and presentations must be written in English. The maximum length allowed for an abstract is 2500 characters (approximately 350 words) including blank spaces. The abstract title, the author(s) or names of institutions are not included in the count of 2500 characters.
Abstract structure and content
In order to make the abstract as informative as possible, please include a brief statement of the purpose of the study and/or the underlying hypotheses, the method used, the results observed, and the conclusions based upon the results. It is inadequate to state “The results will be discussed” or “The data will be presented”. You may subtitle the paragraphs in the following order: Introduction, Objectives, Results, and Conclusion.
The abstract title and body text should only include pharmacopoeia names printed in lower case. Trade names are not allowed. Non-proprietary (generic) names of drugs, written in lower case, are required the first time a drug is mentioned in the text. References, credits or the authors’ academic degrees or grant support are not to be included in the abstract. Standard abbreviations may be employed in the text. Place special or unusual abbreviations in parentheses after the full wording at the first time it appears in the body of the text. Company names are not allowed in the title but can be named in the authors’ affiliation.
Consent for publication of individual patient data - applies to abstracts with identifiable patient information
For the publication of an abstract that contains identifiable information about patients it is necessary that patients have given consent for the research to be published. For all abstracts that include identifiable patient details (e.g. gender, age, illness, location) or images, written informed consent for the publication of these must be obtained from the patient (or their parent or legal guardian).
It is the author’s responsibility to obtain written informed consent for publication of clinical details and/or clinical images from the patient/parent/guardian/relative of the patient. A respective statement needs to be included in the abstract text.
Duplication of publications
EAACI does not accept re-submissions; abstracts must correspond to original, previously unpublished work. By submitting an abstract, the author confirms that the abstract was not presented/published at another meeting, and that the full paper was neither submitted not published.
Declaration of Conflict of Interest
EAACI is committed to ensuring the integrity of its scientific, educational, and research programmes. Abstract submission requires disclosure of any financial or other interest that might be construed as resulting in an actual, potential, or apparent conflict. The submitter is responsible for obtaining disclosure information from all co-authors, to be entered in the author section of the submission page.
Presentation formats and abstract topics
Accepted abstracts selected by expert reviewers will be presented in any of the following sessions: Oral Abstract Sessions, Poster Discussion Sessions (electronic posters) and Thematic Poster Sessions (regular paper posters). Authors can indicate their choice of preferred type of presentation in the provided space. In addition, authors should indicate the thematic area (see Abstract Topics) their abstract should be assigned to. Please note that the final decisions regarding the allocation and the type of presentation of the submitted abstract will be made by the Scientific Programme Committee.
It is the author’s responsibility to submit a correct abstract. Any errors in spelling, grammar or scientific fact will be reproduced as typed by the author as no editing will be done by EAACI. Please note that each year a number of abstracts are rejected because of poor English or because they contain no/incomplete data.
The accepted abstracts will be presented in three formats; Oral Abstract Sessions, Poster Discussion Sessions and Thematic Poster Sessions. All presenting authors will receive detailed guidelines as soon as their abstract has been accepted.
Oral Abstract Session
The Oral Abstract Sessions (OAS) consist of six presentations of eight minutes each and each followed by four minutes for discussion. The sessions are introduced by a lecture given by one of the chairs. As presenter you are required to prepare a MS PowerPoint presentation featuring the main findings of your work.
Tel.: +41 44 205 55 33
Fax: +41 44 205 55 39
Tel.: +41 44 205 55 33
Fax: +41 44 205 55 39